Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 972-976

  Citron, Diane M ^a   Warren, Yumi A ^a   Tyrrell, Kerin L ^a   Merriam, Vreni ^a   Goldstein, Ellie J C ^a,b  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C. difficile infection; Colonization resistance; Normal gut flora

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CLINDAMYCIN; METRONIDAZOLE; MOXIFLOXACIN; REP 3123; UNCLASSIFIED DRUG; VANCOMYCIN;

AGAR DILUTION; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIFIDOBACTERIUM; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM RAMOSUM; CONTROLLED STUDY; CULTURE MEDIUM; GRAM NEGATIVE ANAEROBIC BACTERIA; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; NONHUMAN; SPECIES COMPARISON;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BENZOPYRANS; ENZYME INHIBITORS; GASTROINTESTINAL TRACT; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; THIOPHENES;

EID: 64649101652     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp037     Document Type: Article

References (14)

1. Ricciardi R, Rothenberger DA, Madoff RD et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142 624-31.
2. Pepin J, Valiquette L, Gagnon S et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102: 2781-8.
3. Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis 2006; 43: 428-31.
4. Bhalla A, Pultz NJ, Ray AJ et al. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, Gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol 2003; 24: 644-9.
5. Donskey CJ, Chowdhry TK, Hecker MT et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343: 1925-32.
6. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39: 219-26.
7. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994; 38: 409-14.
8. Critchley IA, Young CL, Stone KC et al. Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother 2005; 49: 4247-52.
9. Critchley IA, Green LS, Young CL et al. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother 2009; 63: 954-63.
10. Ochsner UA, Bell SJ, O'Leary AL et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009; 63: 964-71.
11. Clinical Laboratory and Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2007.
12. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366 1079-84.
13. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 48: 4430-4.
14. Hecht DW, Galang MA, Sambol SP et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51: 2716-9.